The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.
|Videos|April 22, 2014
A Discussion of the CLL11 Trial
Author(s)William G. Wierda, MD, PhD
William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the CLL11 trial, a three-arm trial comparing chlorambucil versus chlorambucil plus rituximab versus chlorambucil plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL).
Advertisement
William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the CLL11 trial, a three-arm trial comparing chlorambucil versus chlorambucil plus rituximab versus chlorambucil plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL).
Clinical Pearls:
- This trial showed that chlorambucil plus obinutuzumab was superior over the other two arms
- To be eligible for this trial, patients needed to have a SEER score higher than 6, which reflects comorbidities associated with age (over age 65 or 70) or renal insufficiency
- The data support that obinutuzumab plus chlorambucil is a superior treatment over other options for the elderly patient population or patients with comorbidities
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
The FDA granted orphan drug designation to Cardiff Oncology’s PLK1 inhibitor onvansertib for relapsed or refractory CMML after early phase 1 activity.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5